CIPLA vs WINDLAS: Stock Comparison

Cipla Ltd vs Windlas Biotech Ltd

Live data: 22 July 2026, 2:34 PM IST • Source: NSE and company filings

Cipla Ltd is the larger company by market capitalisation. Cipla Ltd shows a higher dividend yield, lower leverage and a higher net margin, while Windlas Biotech Ltd shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Cipla Ltd and Windlas Biotech Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, CIPLA is more favourable on 5 of 13 scored metrics and WINDLAS on 8These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CIPLA is the larger company
₹1.14 L Cr vs ₹1,781 Cr
P/E Ratio
WINDLAS has a lower P/E
28x vs 29.83x
P/B Ratio
WINDLAS has a lower P/B
3.2x vs 3.36x
EPS
CIPLA has higher earnings per share
₹48.01 vs ₹31.5
Dividend Yield
CIPLA has a higher dividend yield
0.9% vs 0.72%
Revenue Growth (TTM YoY)
WINDLAS has faster revenue growth
17.7% vs -2.1%
EPS Growth (TTM YoY)
WINDLAS has faster EPS growth
-2.6% vs -54.6%
Qtr Sales Growth
WINDLAS has stronger quarterly sales growth
17.7% vs -2.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCIPLAWINDLAS
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricCIPLAWINDLAS
Live Price₹1,410.9₹877.5
Day Change-1.51%-0.34%
Volume12.88 L28,984
52-Week High₹1,673₹1,097.9
52-Week Low₹1,165.7₹697.4
Distance from 52W High-15.67%-20.07%

Valuation

MetricCIPLAWINDLAS
Market Cap₹1.14 L Cr₹1,781 Cr
P/E Ratio29.83x28x
P/B Ratio3.36x3.2x
EPS₹48.01₹31.5
Book Value₹426.25₹275
Dividend Yield0.9%0.72%

Growth

MetricCIPLAWINDLAS
Revenue Growth (TTM YoY)-2.1%17.7%
EPS Growth (TTM YoY)-54.6%-2.6%
Qtr Sales Growth-2.8%17.7%
Qtr Profit Growth-54.6%-1.78%

Profitability & Leverage

MetricCIPLAWINDLAS
ROE11.6%12.2%
ROCE15.5%15.9%
Net Margin13.96%7.35%
Operating Margin20.9%11.6%
Debt to Equity0.02x0.06x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricCIPLAWINDLAS
Promoter Holding9.17%63.31% 1.41 pp
FII Holding22.56% 1.37 pp2.04% 1.44 pp
DII Holding31.97% 1.25 pp9.84% 1.97 pp
Public Holding16.25% 0.12 pp24.8% 0.9 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Cipla Ltd and Windlas Biotech Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.